Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress.
Md Jamal HossainS M Abdur RahmanPublished in: Expert review of anti-infective therapy (2020)
Currently, palliative care, ranging from outpatient management to intensive care, including oxygen administration, ventilator support, intravenous fluids therapy, with some repurposed drugs, are the primary weapons to fight against COVID-19. Until a safe and effective vaccine is developed, an evidence-based drug repurposing strategy might be the wisest option to save people from this catastrophe. Several existing drugs are now under clinical trials, and some of them are approved in different places of the world for emergency use or as adjuvant therapy in COVID-19 with standard of care.
Keyphrases
- palliative care
- coronavirus disease
- sars cov
- clinical trial
- respiratory syndrome coronavirus
- healthcare
- advanced cancer
- public health
- emergency department
- drug induced
- high dose
- acute respiratory distress syndrome
- quality improvement
- pain management
- stem cells
- intensive care unit
- bone marrow
- smoking cessation
- study protocol